Taurolidine in Haemodialysis Catheter Related Bacteraemia (NCT01243710) | Clinical Trial Compass
CompletedPhase 4
Taurolidine in Haemodialysis Catheter Related Bacteraemia
United Kingdom27 participantsStarted 2010-08
Plain-language summary
The purpose of this study is to determine whether taurolidine with heparin locking solution prevents recurrence of central venous catheter related blood stream infections in haemodialysis patients.
Who can participate
Age range
18 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Haemodialysis patients established on dialysis for greater than 90 days who dialyse in-centre at any of the satellite dialysis units of Imperial College Healthcare NHS Trust
* All patients with a recent catheter related bacteraemia with an identified organism grown on microbiological culture and treated without catheter removal will be eligible for inclusion.
Exclusion Criteria:
* Those individuals in whom attempted catheter salvage is clinically not indicated.
* Unable to provide informed consent
* Known allergy to sodium citrate, heparin or taurolidine.
* Bleeding diathesis or physical cause for active bleeding.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tested taurolidine as a catheter lock solution to prevent bacteria from surviving in the catheter — is taurolidine something that could be used with my dialysis catheter, and how does it compare to whatever lock solution is currently being used for me?
2Since this was a Phase 4 trial, meaning it was studying a treatment already approved for some uses, what does my doctor know about the safety and effectiveness data that came out of this completed study?
3The trial measured how long patients went without a catheter-related bloodstream infection — based on those results, does my doctor think a taurolidine lock solution would meaningfully reduce my personal risk of infection given my situation?
4Catheter-related infections can be serious for dialysis patients — if I am already at higher risk for these infections, should we be discussing this kind of preventive approach now, or is there a standard-of-care option my doctor would recommend first?
5Are there any reasons specific to my health history — like allergies, other medications, or my kidney disease stage — that would make taurolidine a poor fit for me, and is this approach something my care team can actually offer at my dialysis centre?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Duration of bacteraemia-free catheter survival
Timeframe: Catheter survival measured up to six months from enrollment date.